Levosimendan use reduces matrix metalloproteinase-2 in patients with decompensated heart failure

Cardiovascular Drugs and Therapy

Volumn 19, Issue 6, 2005, Pages 399-402

  Tziakas, Dimitrios N ^a   Chalikias, Georgios K ^a   Hatzinikolaou, Helen I ^a   Stakos, Dimitrios A ^a   Papanas, Nikolaos ^a   Tentes, Ioannis K ^a   Kortsaris, Alexandros X ^a   Maltezos, Efstratios ^a   Hatseras, Dimitrios I ^a   Kaski, Juan Carlos ^b  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Extracellular matrix; Heart failure; Left ventricular remodeling; Levosimendan; Matrix metalloproteinases

Indexed keywords

CALCIUM SENSITIZER; GELATINASE A; LEVOSIMENDAN; PLACEBO;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CELL METABOLISM; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE; HEART VENTRICLE REMODELING; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SERUM; STATISTICAL SIGNIFICANCE;

AGED; CARDIOTONIC AGENTS; DISEASE PROGRESSION; FEMALE; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; HYDRAZONES; INJECTIONS, INTRAVENOUS; MALE; MATRIX METALLOPROTEINASE 2; PLACEBOS; PYRIDAZINES; TREATMENT OUTCOME;

EID: 32444444374     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-005-5417-5     Document Type: Article

References (15)

1. Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol 1997;80:15L-25L.
2. Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart. N Engl J Med 1997;336:1131-1141.
3. Werb Z, Alexander CM. Proteinases and matrix degredation. In: Kelly WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of Rheumatology. New York NY: WB Saunders. 1993:248-268.
4. Li YY, Mc Tiernan CF, Feldman AM. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 2000;46:214-224.
5. Endoh M. Mechanisms of action of novel cardiotonic agents. J Cardiovasc Pharmacology 2002;40:323-338.
6. Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:384-416.
7. Milo O, Cotter G, Kaluski E, et al. Comparison of inflammatory and neurohormonal activation in cardiogenic pulmonary edema secondary to ischemic versus nonischemic causes. Am J Cardiol 2003;92:222-226.
8. Sato Y, Takatsu Y, Kataoka K, et al. Serial concentrations of C-reactive protein, interleukin (IL)-4, and IL-6 in patients with acute left heart decompensation. Clin Cardiol 1999;22:811-813.
9. Parissis JT, Adamopoulos S, Antoniades C, et al. Effects of Levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis markers in patients with decompensated advanced heart failure. Am J Cardiol 2004;93:1309-1312.
10. Parissis JT, Panou F, Farmakis D, et al. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol 2005;96:423-426.
11. Fujisawa T, Hattori T, Takahashi K, Kuboki T, Yamashita A, Takigawa M. Cyclic mechanical stress induces extracellular matrix degradation in cultured chondrocytes via gene expression of matrix metalloproteinases and interleukin-1. J Biochem 1999;125:966-975.
12. Bishop JE. Regulation of cardiovascular collagen deposition by mechanical forces. Mol Med Today 1998;4:69-75.
13. Yamazaki T, Lee JD, Shimizu H, Uzui H, Ueda T. Circulating matrix metalloproteinase-2 is elevated in patients with congestive heart failure. Eur J Heart Fail 2004;6:41-45.
14. Tsuruda T, Boerrigter G, Huntley BK, et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 2002;91:1127-1134.
15. Li YY, McTiernan CF, Feldman AM. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 2000;46:214-224.